Table 3 Summary of PK parameters derived from non-compartmental analysis (Mean ± SEM)

From: Increased imaging ligand hydrophilicity and improved pharmacokinetic properties provides enhanced in vivo targeting of fibroblast activation protein

Reagents

C0 (nM)

Terminal t1/2 (h)

AUC0-inf (nM*h)

VD,ss (ml)

Cl (ml/h)

FAPIa

50 ± 7

0.5 ± 0.1

14 ± 4

62.7 ± 18.4

234 ± 98

FAPI-ALB

189 ± 52

0.9 ± 0.0

88 ± 18

14.5 ± 8.4

25.2 ± 6.2

FAPI-AF647

1488 ± 30

2.1 ± 0.2

626 ± 46

8.0 ± 0.5

3.23 ± 0.23

FAPI-800CW

1252 ± 52

1.0 ± 0.1

525 ± 25

3.9 ± 0.2

3.83 ± 0.19

FAPI-ALB-AF647

2028 ± 113

5.6 ± 0.1

7326 ± 162

1.3 ± 0.1

0.27 ± 0.01

FAPI-ALB-800CW

1835 ± 129

5.3 ± 0.1

6104 ± 190

1.4 ± 0.1

0.33 ± 0.01

  1. aFAPI was delivered at a higher dose than other conjugates to maintain concentration above LLOQ during sampling. Concentration data for this probe has been linearly dose normalized to 2 nmol for consistency to other probes.
Back to article page